Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
Abstract Background Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-03-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-021-01720-w |
| _version_ | 1819133491025018880 |
|---|---|
| author | Pochamana Phisalprapa Ratthanon Prasitwarachot Chayanis Kositamongkol Pranaidej Hengswat Weerachai Srivanichakorn Chaiwat Washirasaksiri Sombat Treeprasertsuk Phunchai Charatcharoenwitthaya Nathorn Chaiyakunapruk |
| author_facet | Pochamana Phisalprapa Ratthanon Prasitwarachot Chayanis Kositamongkol Pranaidej Hengswat Weerachai Srivanichakorn Chaiwat Washirasaksiri Sombat Treeprasertsuk Phunchai Charatcharoenwitthaya Nathorn Chaiyakunapruk |
| author_sort | Pochamana Phisalprapa |
| collection | DOAJ |
| description | Abstract Background Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding the economic burden of NASH in low- and middle-income countries (LMICs). The aim of this study was to estimate the economic burden of NASH in Thailand as a lesson learned for LMICs. Methods To estimate the healthcare costs and prevalence of NASH with significant fibrosis (fibrosis stage ≥ 2) in the general Thai population, an eleven-state lifetime horizon Markov model with 1-year cycle length was performed. The model comprised Thai population aged 18 years and older. The cohort size was based on Thailand Official Statistic Registration Systems. The incidence of NASH, transitional probabilities, and costs-of-illness were based on previously published literature, including systematic reviews and meta-analyses. The age-specific prevalence of NASH was based on Thai NASH registry data. Costs were expressed in 2019 US Dollars ($). As we undertook analysis from the payer perspective, only direct medical costs were included. All future costs were discounted at an annual rate of 3%. A series of sensitivity analyses were performed. Results The estimated total number of patients with significant NASH was 2.9 million cases in 2019, based on a NASH prevalence of 5.74%. The total lifetime cost of significant NASH was $15.2 billion ($5,147 per case), representing approximately 3% of the 2019 GDP of Thailand. The probabilistic sensitivity analysis showed that the lifetime costs of significant NASH varied from $11.4 billion to $18.2 billion. Conclusions The economic burden associated with NASH is substantial in Thailand. This prompts clinicians and policy makers to consider strategies for NASH prevention and management. |
| first_indexed | 2024-12-22T09:48:08Z |
| format | Article |
| id | doaj.art-cb55e481b07f4334aa4c8a6a9543c4e9 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-22T09:48:08Z |
| publishDate | 2021-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-cb55e481b07f4334aa4c8a6a9543c4e92022-12-21T18:30:29ZengBMCBMC Gastroenterology1471-230X2021-03-0121111010.1186/s12876-021-01720-wEconomic burden of non-alcoholic steatohepatitis with significant fibrosis in ThailandPochamana Phisalprapa0Ratthanon Prasitwarachot1Chayanis Kositamongkol2Pranaidej Hengswat3Weerachai Srivanichakorn4Chaiwat Washirasaksiri5Sombat Treeprasertsuk6Phunchai Charatcharoenwitthaya7Nathorn Chaiyakunapruk8Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Pharmacy Technicians, Sirindhorn College of Public Health SuphanburiDivision of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityFaculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red CrossDivision of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Pharmacotherapy, College of Pharmacy, University of UtahAbstract Background Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding the economic burden of NASH in low- and middle-income countries (LMICs). The aim of this study was to estimate the economic burden of NASH in Thailand as a lesson learned for LMICs. Methods To estimate the healthcare costs and prevalence of NASH with significant fibrosis (fibrosis stage ≥ 2) in the general Thai population, an eleven-state lifetime horizon Markov model with 1-year cycle length was performed. The model comprised Thai population aged 18 years and older. The cohort size was based on Thailand Official Statistic Registration Systems. The incidence of NASH, transitional probabilities, and costs-of-illness were based on previously published literature, including systematic reviews and meta-analyses. The age-specific prevalence of NASH was based on Thai NASH registry data. Costs were expressed in 2019 US Dollars ($). As we undertook analysis from the payer perspective, only direct medical costs were included. All future costs were discounted at an annual rate of 3%. A series of sensitivity analyses were performed. Results The estimated total number of patients with significant NASH was 2.9 million cases in 2019, based on a NASH prevalence of 5.74%. The total lifetime cost of significant NASH was $15.2 billion ($5,147 per case), representing approximately 3% of the 2019 GDP of Thailand. The probabilistic sensitivity analysis showed that the lifetime costs of significant NASH varied from $11.4 billion to $18.2 billion. Conclusions The economic burden associated with NASH is substantial in Thailand. This prompts clinicians and policy makers to consider strategies for NASH prevention and management.https://doi.org/10.1186/s12876-021-01720-wNon-alcoholic steatohepatitisNASHSignificant fibrosisEconomic burdenCost of illnessPrevalence |
| spellingShingle | Pochamana Phisalprapa Ratthanon Prasitwarachot Chayanis Kositamongkol Pranaidej Hengswat Weerachai Srivanichakorn Chaiwat Washirasaksiri Sombat Treeprasertsuk Phunchai Charatcharoenwitthaya Nathorn Chaiyakunapruk Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand BMC Gastroenterology Non-alcoholic steatohepatitis NASH Significant fibrosis Economic burden Cost of illness Prevalence |
| title | Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand |
| title_full | Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand |
| title_fullStr | Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand |
| title_full_unstemmed | Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand |
| title_short | Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand |
| title_sort | economic burden of non alcoholic steatohepatitis with significant fibrosis in thailand |
| topic | Non-alcoholic steatohepatitis NASH Significant fibrosis Economic burden Cost of illness Prevalence |
| url | https://doi.org/10.1186/s12876-021-01720-w |
| work_keys_str_mv | AT pochamanaphisalprapa economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT ratthanonprasitwarachot economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT chayaniskositamongkol economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT pranaidejhengswat economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT weerachaisrivanichakorn economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT chaiwatwashirasaksiri economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT sombattreeprasertsuk economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT phunchaicharatcharoenwitthaya economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand AT nathornchaiyakunapruk economicburdenofnonalcoholicsteatohepatitiswithsignificantfibrosisinthailand |